Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
IMA
ImageneBio, Inc.
CAPPED RATING
ImageneBio, Inc. (IMA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (D). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Overall Rating
2.2
/ 5.0
C
Value
B+
Factor Score
3.6
/ 5.0
Growth
D
Factor Score
1.4
/ 5.0
Profitability
D+
Factor Score
1.8
/ 5.0
Momentum
D+
Factor Score
1.7
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-0.9
EV / EBITDA
1.5
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-36.6%
Price Return 12M
-54.6%
Catalyst Signal
0.00
Market Cap
$46.3M
TTM Revenue
$0.0
Price / Sales
N/A
ROE
-82.7%
Historical Factor Score Progression
Held C for 5 weeks
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B+ (3.6) | D (1.4) | D+ (1.8) | D+ (1.7) | C+ (2.6) | C (2.2) |
| 2026-11-05 | B+ (3.8) | D (1.3) | D+ (1.8) | C- (1.9) | C+ (2.7) | C (2.3) |
| 2026-10-29 | B+ (3.6) | D (1.3) | D+ (1.8) | D+ (1.7) | C+ (2.7) | C (2.2) |
| 2026-10-22 | B+ (3.6) | D (1.3) | D+ (1.8) | D+ (1.8) | C+ (2.6) | C (2.2) |
| 2026-10-15 | B+ (3.6) | D (1.3) | D+ (1.8) | C- (2.0) | C+ (2.6) | C (2.3) |
Page
1
of
4